Century Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPSC research report →
Range $2 – $19
Price Chart
About the company
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy.
- CEO
- Brent Pfeiffenberger
- IPO
- 2021
- Employees
- 78
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on IPSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $256.22M
- P/E
- -1.36
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.25
- EV/EBITDA
- -2.54
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.76%
- ROIC
- -43.66%
Latest fiscal year · YoY change
- Revenue
- $109.16M+1556.8%
- Gross Profit
- $96.06M+1357.9%
- Op Income
- $-15,040,000
- Net Income
- $-9,580,000+92.4%
- EPS
- $-0.11+93.2%
- OCF Growth
- +5.7%
- FCF Growth
- +5.0%
- 52W High
- $3.04
- 52W Low
- $0.43
- 50D MA
- $1.95
- 200D MA
- $2.07
- Beta
- 1.60
- RSI (14)
- 24
- Avg Volume
- 639.79K
No earnings-call transcripts are available for IPSC yet.
- Free Float
- 55.9%
- Shares Outstanding
- 181.08M
- Float Shares
- 101.25M
of shares held by institutions
74 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 17.75M | 0 |
| Tcg Crossover Management, LLC | 17.75M | 0 |
| Versant Venture Management, LLC | 12.17M | 0 |
| Deep Track Capital, LP | 9.46M | ▼ 25.10K |
| Vr Adviser, LLC | 8.70M | 0 |
| Rtw Investments, LP | 8.70M | 0 |
| Commodore Capital LP | 8.70M | 0 |
| Blackrock, Inc. | 8.09M | ▲ 6.57M |
| Vanguard Capital Management LLC | 5.70M | ▲ 17.48K |
| Balyasny Asset Management L.P. | 5.52M | ▲ 505.21K |
| Point72 Asset Management, L.P. | 4.98M | ▼ 984.15K |
| Seven Fleet Capital Management LP | 4.35M | ▲ 1.40M |
Held by 96 ETFs
Biggest fund positions in IPSC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 14, 26 | Russotti Gregory | sell | 2,587 |
| Sep 14, 26 | Carr Douglas | sell | 1,658 |
| Sep 11, 26 | Pfeiffenberger Brent | other | 13,850 |
| Sep 9, 26 | Truitt Joseph | other | 148,000 |
| Sep 9, 26 | Truitt Joseph | other | 0 |
| Sep 4, 26 | Pfeiffenberger Brent | other | 463 |
| Sep 8, 26 | Russotti Gregory | sell | 534 |
| Sep 8, 26 | Carr Douglas | sell | 254 |
| Aug 14, 26 | Pfeiffenberger Brent | other | 31,172 |
| Aug 3, 26 | Carr Douglas | sell | 275 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IPSC coverage
Recent articles, reports, and earnings notes.
No research on IPSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPSC report →Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis
defenseworld.net · Oct 4
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
globenewswire.com · Oct 2
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
seekingalpha.com · Sep 30
Century Therapeutics Appoints Joseph Truitt to Board of Directors
globenewswire.com · Sep 9
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
globenewswire.com · Aug 12
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
businesswire.com · Jul 23
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
globenewswire.com · Jul 9
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
globenewswire.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.